Literature DB >> 31678478

Identification of inhibitors of dengue viral replication using replicon cells expressing secretory luciferase.

Fumihiro Kato1, Yasunori Nio2, Kazumi Yagasaki3, Rieko Suzuki4, Makoto Hijikata5, Tomoyuki Miura6, Isao Miyazaki7, Shigeru Tajima8, Chang-Kweng Lim8, Masayuki Saijo8, Tomohiko Takasaki9, Takayuki Hishiki10.   

Abstract

Dengue virus (DENV) is the causative agent of dengue fever (DF), dengue haemorrhagic fever (DHF), and dengue shock syndrome (DSS) and continues to be a public health problem in the tropical and subtropical areas. However, there is currently no antiviral treatment for DENV infection. In this study, our aim was to develop a stable reporter replicon cell system that supports constant viral RNA replication in cultured cells. The isolated replicon cells exhibited high levels of luciferase activity in the culture supernatant concomitant with expression of virus-encoded NS1, NS3 and NS5 proteins in the cells. The NS1, NS3 proteins and dsRNA were detected in the replicon cells by immunofluorescence analysis. Furthermore, the anti-DENV inhibitors ribavirin and bromocriptine significantly reduced the luciferase activity in a dose-dependent manner. High-throughput screening with a compound library using the stably-transfected replicon cells showed a Z' factor value of 0.57. Our screening yielded several candidates including one compound that has already shown anti-DENV activity. Taken together, our results demonstrate that this DENV subgenomic replicon cell system expressing a secretory luciferase gene can be useful for the high-throughput screening of anti-DENV compounds and the analysis of the replication mechanism of the DENV RNA.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral drug; Dengue virus; Gaussia luciferase; High-throughput screening; Replicon

Mesh:

Substances:

Year:  2019        PMID: 31678478     DOI: 10.1016/j.antiviral.2019.104643

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches.

Authors:  Sakshi Kamboj; Akanksha Rajput; Amber Rastogi; Anamika Thakur; Manoj Kumar
Journal:  Comput Struct Biotechnol J       Date:  2022-06-30       Impact factor: 6.155

Review 2.  Antiviral Compounds for Blocking Arboviral Transmission in Mosquitoes.

Authors:  Shengzhang Dong; George Dimopoulos
Journal:  Viruses       Date:  2021-01-14       Impact factor: 5.048

3.  Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.

Authors:  Fumihiro Kato; Shutoku Matsuyama; Miyuki Kawase; Takayuki Hishiki; Hiroshi Katoh; Makoto Takeda
Journal:  Microbiol Immunol       Date:  2020-07-25       Impact factor: 2.962

4.  Development of A MERS-CoV Replicon Cell Line for Antiviral Screening.

Authors:  Jing Chen; Bing-Jie Hu; Kai Zhao; Yun Luo; Hao-Feng Lin; Zheng-Li Shi
Journal:  Virol Sin       Date:  2021-02-22       Impact factor: 4.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.